Treatment of comorbid migraine and temporomandibular disorders: A factorial, double-blind, randomized, placebo-controlled study
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.11607/jop.1096 http://hdl.handle.net/11449/227481 |
Resumo: | Aims: To investigate the effectiveness of single and concomitant treatment of migraine and temporomandibular disorders (TMD) in women with the comorbidity. Methods: Eligible female patients met International Classification of Headache Disorders, second edition (ICHD-2) criteria for migraine with or without aura and the Research Diagnostic Criteria for myofascial TMD (Grade ll or lll). After a run-in period (30 days), women with both migraine and TMD were enrolled into a four-arm, double-blind, placebocontrolled, factorial study testing the separate and joint effects of a migraine treatment (propranolol 90 mg) and a TMD treatment (stabilization splint [SS]) in four groups of patients. The four treatment groups were propranolol and SS (n = 22); propranolol placebo and SS (n = 23); propranolol and non-occlusal splint (NOS) (n = 23); and propranolol placebo and NOS (n = 21). The primary endpoint for migraine was change in headache days from baseline to the third month, and the secondary endpoint was change in days with at least moderate headache in the same period. The TMD endpoints included pain threshold and mandibular vertical range of motion. Data were analyzed using analysis of variance (ANOVA, Dunn's post-hoc test) or Kruskal-Wallis test. Results: For the primary endpoint, in intention-to-treat (ITT) analyses (n = 94), propranolol and SS were associated with a nonsignificant reduction in the number of headache days, relative to all other groups. For per-protocol (PP) Completer analyses (n = 89), differences in the number of headache days reached significance (P < .05). The propranolol and SS group was significantly superior to the other groups on all other headache endpoints and in disability, in both ITT and PP analyses. No significant differences among groups were seen for the TMD parameters. Conclusion: In women with TMD and migraine, migraine significantly improved only when both conditions were treated. The best treatment choice for TMD pain in women with migraine is yet to be defined. |
id |
UNSP_ae6481d5f55c24b76e8d63ccf1b95b1a |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/227481 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Treatment of comorbid migraine and temporomandibular disorders: A factorial, double-blind, randomized, placebo-controlled studyClinical trialMigraineOcclusal splintPropranololTemporomandibular disordersAims: To investigate the effectiveness of single and concomitant treatment of migraine and temporomandibular disorders (TMD) in women with the comorbidity. Methods: Eligible female patients met International Classification of Headache Disorders, second edition (ICHD-2) criteria for migraine with or without aura and the Research Diagnostic Criteria for myofascial TMD (Grade ll or lll). After a run-in period (30 days), women with both migraine and TMD were enrolled into a four-arm, double-blind, placebocontrolled, factorial study testing the separate and joint effects of a migraine treatment (propranolol 90 mg) and a TMD treatment (stabilization splint [SS]) in four groups of patients. The four treatment groups were propranolol and SS (n = 22); propranolol placebo and SS (n = 23); propranolol and non-occlusal splint (NOS) (n = 23); and propranolol placebo and NOS (n = 21). The primary endpoint for migraine was change in headache days from baseline to the third month, and the secondary endpoint was change in days with at least moderate headache in the same period. The TMD endpoints included pain threshold and mandibular vertical range of motion. Data were analyzed using analysis of variance (ANOVA, Dunn's post-hoc test) or Kruskal-Wallis test. Results: For the primary endpoint, in intention-to-treat (ITT) analyses (n = 94), propranolol and SS were associated with a nonsignificant reduction in the number of headache days, relative to all other groups. For per-protocol (PP) Completer analyses (n = 89), differences in the number of headache days reached significance (P < .05). The propranolol and SS group was significantly superior to the other groups on all other headache endpoints and in disability, in both ITT and PP analyses. No significant differences among groups were seen for the TMD parameters. Conclusion: In women with TMD and migraine, migraine significantly improved only when both conditions were treated. The best treatment choice for TMD pain in women with migraine is yet to be defined.Department of Dental Materials and Prosthodontics UNESP-Univ Estadual Paulista Campus AraraquaraDepartment of Neurology School of Medicine University of São Paulo Ribeirao PretoMontefiore Headache Center Albert Einstein College of MedicineLabrys Biologics IncDepartment of Dental Materials and Prosthodontics UNESP-Univ Estadual Paulista Campus AraraquaraUniversidade Estadual Paulista (UNESP)Universidade de São Paulo (USP)Albert Einstein College of MedicineIncGonçalves, Daniela A.G. [UNESP]Camparis, Cinara M. [UNESP]Speciali, José G.Castanharo, Sabrina M. [UNESP]Ujikawa, Liliana T.Lipton, Richard B.Bigal, Marcelo E.2022-04-29T07:13:26Z2022-04-29T07:13:26Z2013-01-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article325-335http://dx.doi.org/10.11607/jop.1096Journal of Oral and Facial Pain and Headache, v. 27, n. 4, p. 325-335, 2013.2333-03762333-0384http://hdl.handle.net/11449/22748110.11607/jop.10962-s2.0-84892697740Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengJournal of Oral and Facial Pain and Headacheinfo:eu-repo/semantics/openAccess2022-04-29T07:13:26Zoai:repositorio.unesp.br:11449/227481Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462022-04-29T07:13:26Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Treatment of comorbid migraine and temporomandibular disorders: A factorial, double-blind, randomized, placebo-controlled study |
title |
Treatment of comorbid migraine and temporomandibular disorders: A factorial, double-blind, randomized, placebo-controlled study |
spellingShingle |
Treatment of comorbid migraine and temporomandibular disorders: A factorial, double-blind, randomized, placebo-controlled study Gonçalves, Daniela A.G. [UNESP] Clinical trial Migraine Occlusal splint Propranolol Temporomandibular disorders |
title_short |
Treatment of comorbid migraine and temporomandibular disorders: A factorial, double-blind, randomized, placebo-controlled study |
title_full |
Treatment of comorbid migraine and temporomandibular disorders: A factorial, double-blind, randomized, placebo-controlled study |
title_fullStr |
Treatment of comorbid migraine and temporomandibular disorders: A factorial, double-blind, randomized, placebo-controlled study |
title_full_unstemmed |
Treatment of comorbid migraine and temporomandibular disorders: A factorial, double-blind, randomized, placebo-controlled study |
title_sort |
Treatment of comorbid migraine and temporomandibular disorders: A factorial, double-blind, randomized, placebo-controlled study |
author |
Gonçalves, Daniela A.G. [UNESP] |
author_facet |
Gonçalves, Daniela A.G. [UNESP] Camparis, Cinara M. [UNESP] Speciali, José G. Castanharo, Sabrina M. [UNESP] Ujikawa, Liliana T. Lipton, Richard B. Bigal, Marcelo E. |
author_role |
author |
author2 |
Camparis, Cinara M. [UNESP] Speciali, José G. Castanharo, Sabrina M. [UNESP] Ujikawa, Liliana T. Lipton, Richard B. Bigal, Marcelo E. |
author2_role |
author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Estadual Paulista (UNESP) Universidade de São Paulo (USP) Albert Einstein College of Medicine Inc |
dc.contributor.author.fl_str_mv |
Gonçalves, Daniela A.G. [UNESP] Camparis, Cinara M. [UNESP] Speciali, José G. Castanharo, Sabrina M. [UNESP] Ujikawa, Liliana T. Lipton, Richard B. Bigal, Marcelo E. |
dc.subject.por.fl_str_mv |
Clinical trial Migraine Occlusal splint Propranolol Temporomandibular disorders |
topic |
Clinical trial Migraine Occlusal splint Propranolol Temporomandibular disorders |
description |
Aims: To investigate the effectiveness of single and concomitant treatment of migraine and temporomandibular disorders (TMD) in women with the comorbidity. Methods: Eligible female patients met International Classification of Headache Disorders, second edition (ICHD-2) criteria for migraine with or without aura and the Research Diagnostic Criteria for myofascial TMD (Grade ll or lll). After a run-in period (30 days), women with both migraine and TMD were enrolled into a four-arm, double-blind, placebocontrolled, factorial study testing the separate and joint effects of a migraine treatment (propranolol 90 mg) and a TMD treatment (stabilization splint [SS]) in four groups of patients. The four treatment groups were propranolol and SS (n = 22); propranolol placebo and SS (n = 23); propranolol and non-occlusal splint (NOS) (n = 23); and propranolol placebo and NOS (n = 21). The primary endpoint for migraine was change in headache days from baseline to the third month, and the secondary endpoint was change in days with at least moderate headache in the same period. The TMD endpoints included pain threshold and mandibular vertical range of motion. Data were analyzed using analysis of variance (ANOVA, Dunn's post-hoc test) or Kruskal-Wallis test. Results: For the primary endpoint, in intention-to-treat (ITT) analyses (n = 94), propranolol and SS were associated with a nonsignificant reduction in the number of headache days, relative to all other groups. For per-protocol (PP) Completer analyses (n = 89), differences in the number of headache days reached significance (P < .05). The propranolol and SS group was significantly superior to the other groups on all other headache endpoints and in disability, in both ITT and PP analyses. No significant differences among groups were seen for the TMD parameters. Conclusion: In women with TMD and migraine, migraine significantly improved only when both conditions were treated. The best treatment choice for TMD pain in women with migraine is yet to be defined. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-01-01 2022-04-29T07:13:26Z 2022-04-29T07:13:26Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.11607/jop.1096 Journal of Oral and Facial Pain and Headache, v. 27, n. 4, p. 325-335, 2013. 2333-0376 2333-0384 http://hdl.handle.net/11449/227481 10.11607/jop.1096 2-s2.0-84892697740 |
url |
http://dx.doi.org/10.11607/jop.1096 http://hdl.handle.net/11449/227481 |
identifier_str_mv |
Journal of Oral and Facial Pain and Headache, v. 27, n. 4, p. 325-335, 2013. 2333-0376 2333-0384 10.11607/jop.1096 2-s2.0-84892697740 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Journal of Oral and Facial Pain and Headache |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
325-335 |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1803649693841883136 |